Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17791970 | 1.00 | RAB9A (0.33) | RAB9AKDM4EALDH1A1MAOBMEN1 | |
| SCHEMBL17791968 | 0.93 | RAB9A (0.33) | RAB9AKDM4EALDH1A1MAOBMEN1 | |
| SCHEMBL17791975 | 0.92 | — | — | |
| SCHEMBL17791976 | 0.92 | ADORA3 (0.32) | RAB9AKDM4EALDH1A1MAOB | |
| SCHEMBL17791962 | 0.92 | AR (0.30) | RAB9AKDM4EALDH1A1MAOB | |
| SCHEMBL17791988 | 0.92 | ALDH1A1 (0.32) | RAB9AKDM4EALDH1A1MAOB | |
| SCHEMBL17791954 | 0.90 | CYP1A2 (0.37) | RAB9AALDH1A1MAOBERBB2CYP1A2 | |
| SCHEMBL17792008 | 0.90 | CYP1A2 (0.37) | RAB9AALDH1A1MAOBERBB2CYP1A2 | |
| SCHEMBL17791965 | 0.89 | CYP1A2 (0.36) | ALDH1A1ERBB2CYP1A2FYNMAOA | |
| SCHEMBL17791974 | 0.89 | RAB9A (0.33) | RAB9AKDM4EALDH1A1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9793491-B2 | Compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-17 | — | — | US | disclosed |
| US-9793491-B2 | Compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-02 | — | — | US | disclosed |
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | TMEM109, USE1, TRPC1 | RAB9A 1123/4885KDM4E 2736/4885ALDH1A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.